| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 0.73 | -0.01 (-1.35%) | 0.1866 - 1.22 | 213.2 thousand (Above Avg) |
Market data as of 11:46AM 06/19/13. Quotes are delayed by at least 15 min.
| Open | 0.74 |
|---|---|
| Previous Close | 0.74 |
| Day's Range | 0.73 - 0.75 |
| Market Cap | 33.0M |
| Avg Volume (10 Day) | 142.3K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.7 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis
Business Wire - Wednesday 06/05/2013 8:00 AM ET
| IDRA | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -9.26% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | 682.09 |
| Company | Last | Change |
|---|---|---|
| BioSante Pharmaceuticals Inc | 1.24 | -1.59% |
| Verenium Corp | 2.25 | -1.75% |
| Cardiome Pharma Corp | 2.07 | +0.49% |
| Hemispherx Biopharma Inc | 0.25 | -1.52% |
| Merus Labs International Inc | 0.80 | 0.00% |
Data is delayed by at least 15 min.